Table 1.
Characteristics of Patients With CRLM According to KRAS Mutation Status
| No. (%)
|
|||||||
|---|---|---|---|---|---|---|---|
|
KRAS
|
Mutant KRAS
|
||||||
| Characteristic | All Patients | Wild Type | Mutant | P Value | Codon 12 | Codon 13 | P Value |
| Total No. of patients | 331 | 240 | 91 | 67 | 24 | ||
|
| |||||||
| Patient characteristics | |||||||
|
| |||||||
| Male | 206 (61.7) | 150 (62.5) | 56 (61.5) | .87 | 37 (55.2) | 19 (79.2) | .04 |
|
| |||||||
| Age, median (IQR), y | 50.0 (41.5–60.6) | 51.1 (42.3–61.2) | 48.5 (38.6–56.1) | .07 | 48.5 (38.6–56.0) | 47.6 (39.6–57.6) | .93 |
|
| |||||||
| Primary tumor characteristics | |||||||
|
| |||||||
| Rectal primary tumor | 90 (27.2) | 71 (29.6) | 19 (20.9) | .11 | 10 (14.9) | 9 (37.5) | .02 |
|
| |||||||
| T stage (n = 283) | |||||||
|
| |||||||
| T1 or T2 | 44 (15.5) | 33 (16.2) | 11 (13.9) | 8 (13.6) | 3 (15.0) | ||
|
| |||||||
| T3 or T4 | 239 (84.5) | 171 (83.8) | 68 (86.1) | 51 (86.4) | 17 (85.0) | ||
|
| |||||||
| Node-positive primary tumor | 203 (61.3) | 141 (58.8) | 62 (68.1) | .12 | 46 (68.7) | 16 (66.7) | .86 |
|
| |||||||
| Preoperative factors | |||||||
|
| |||||||
| CEA, median (IQR) | 7.6 (3.1–27.0) | 8.7 (3.8–29.7) | 5.1 (2.7–24.9) | .06 | 5.1 (2.7–24.0) | 4.9 (2.7–38.8) | .93 |
|
| |||||||
| Chemotherapy | 224 (67.7) | 163 (67.9) | 61 (67.0) | .88 | 43 (64.2) | 18 (75.0) | .33 |
|
| |||||||
| Disease-free interval <12 mo | 219 (66.2) | 156 (65.0) | 63 (69.2) | .47 | 46 (68.7) | 17 (70.8) | .84 |
|
| |||||||
| CRLM characteristics | |||||||
|
| |||||||
| Synchronous CRLM | 184 (55.6) | 129 (53.8) | 55 (60.4) | .27 | 38 (56.7) | 17 (70.8) | .23 |
|
| |||||||
| No. of CRLM, median (IQR) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | .48 | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | .73 |
|
| |||||||
| Size of largest CRLM, median (IQR) | 2.5 (1.8–3.8) | 2.5 (1.9–4.0) | 2.5 (1.5–3.8) | .23 | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | .86 |
|
| |||||||
| Bilateral disease | 90 (27.2) | 68 (28.3) | 22 (24.2) | .45 | 16 (23.9) | 6 (25.0) | .91 |
|
| |||||||
| Details of surgical procedure | |||||||
|
| |||||||
| Resection only | 269 (81.3) | 195 (81.2) | 74 (81.3) | .99 | 56 (83.6) | 18 (75.0) | .36 |
|
| |||||||
| Resection plus ablation | 62 (18.7) | 45 (18.8) | 17 (18.7) | .99 | 11 (16.4) | 6 (25.0) | .36 |
|
| |||||||
| Major hepatectomy | 142 (42.9) | 101 (42.1) | 41 (45.1) | .63 | 27 (40.3) | 14 (58.3) | .13 |
|
| |||||||
| R0 margin status | 256 (77.3) | 183 (76.2) | 73 (80.2) | .44 | 51 (76.1) | 22 (91.7) | .10 |
|
| |||||||
| Postoperative chemotherapy | 210 (63.4) | 152 (63.3) | 58 (63.7) | .95 | 44 (65.7) | 14 (58.3) | .52 |
|
| |||||||
| Recurrence | 178 (53.8) | 130 (54.2) | 48 (52.7) | .82 | 33 (49.3) | 15 (62.5) | .27 |
|
| |||||||
| Death | 156 (47.1) | 109 (45.4) | 47 (51.7) | .31 | 34 (50.8) | 13 (54.2) | .77 |
Abbreviations: CEA, carcinoembryonic antigen; CRLM, colorectal liver metastases; HR, hazard ratio; IQR, interquartile range. SI conversion factor: To convert CEA to micrograms per liter, multiply by 1.0.